BiomX responds to unusual stock market activity, stating no undisclosed material developments exist.
Quiver AI Summary
BiomX Inc. has issued a statement addressing recent unusual market activity in its common stock, clarifying that it is not aware of any undisclosed material developments or other reasons that could explain the fluctuations. The NYSE American LLC contacted the company as part of its standard procedure, prompting this response. BiomX, a clinical-stage company, focuses on developing phage therapies to target specific pathogenic bacteria, aiming to treat chronic diseases with significant unmet medical needs. The company will not comment further on market speculation or trading activity.
Potential Positives
- BiomX reaffirmed that there are no undisclosed material developments in its business, providing reassurance to investors about the stability of the company.
- The company's statement addresses unusual market activity, demonstrating proactive communication and transparency with its shareholders.
- BiomX highlights its advancement in novel phage therapies, which positions it favorably within a niche market focused on chronic diseases and unmet medical needs.
Potential Negatives
- The company’s acknowledgment of unusual market activity may raise concerns about the stability and confidence in its stock performance.
- The statement's emphasis on a lack of material developments could imply stagnation or a lack of progress in the company's business initiatives.
- The decision not to comment further on market speculation could be viewed as a lack of transparency, potentially leading to investor uncertainty.
FAQ
What is BiomX Inc. known for?
BiomX Inc. specializes in developing natural and engineered phage therapies to target pathogenic bacteria.
Why did BiomX issue a statement regarding market activity?
The Company issued a statement due to unusual market activity in its common stock and received inquiries from NYSE American LLC.
Is there any new information from BiomX about its business?
BiomX is not aware of any new material developments that explain the unusual market activity.
What does BiomX's BOLT platform do?
The BOLT platform customizes phage compositions to target specific bacterial threats in chronic disease treatment.
Where can I find more information about BiomX?
More information about BiomX can be found on their official website at www.biomx.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PHGE Hedge Fund Activity
We have seen 7 institutional investors add shares of $PHGE stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY removed 1,854,032 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $973,366
- ALYESKA INVESTMENT GROUP, L.P. added 1,590,738 shares (+inf%) to their portfolio in Q3 2025, for an estimated $835,137
- AIGH CAPITAL MANAGEMENT LLC removed 1,566,944 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $822,645
- IKARIAN CAPITAL, LLC removed 500,000 shares (-56.0%) from their portfolio in Q3 2025, for an estimated $262,500
- ADAR1 CAPITAL MANAGEMENT, LLC removed 221,942 shares (-74.1%) from their portfolio in Q3 2025, for an estimated $116,519
- CITADEL ADVISORS LLC added 161,781 shares (+inf%) to their portfolio in Q3 2025, for an estimated $84,935
- BOOTHBAY FUND MANAGEMENT, LLC removed 132,913 shares (-56.0%) from their portfolio in Q3 2025, for an estimated $69,779
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PHGE Analyst Ratings
Wall Street analysts have issued reports on $PHGE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/25/2025
To track analyst ratings and price targets for $PHGE, check out Quiver Quantitative's $PHGE forecast page.
Full Release
NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock.
The Company is not aware of any material developments in its business or affairs that have not been previously disclosed, nor, to its knowledge, of any other reason that would account for the recent unusual market activity in its common stock.
NYSE American LLC has contacted the Company in accordance with its usual practice and has advised that the Company issue this statement. The Company does not intend to make any further comment on market speculation or trading activity.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit
www.biomx.com
, the content of which does not form a part of this press release.
Contacts:
BiomX, Inc.
Ben Cohen
Head Corporate Communications
[email protected]
